To assess pharmacologic activity for novel neurologically-active compounds, researchers measure putative biomarkers of psychedelic response, such as brain network segregation or modularity using fMRI and/or PET neuroplasticity changes.

Authors

• Person: Not available Organization: Nature
  Neuroimaging in psychedelic drug development: past, present, and ...

Sources

• Neuroimaging in psychedelic drug development: past, present, and ... www.nature.com Nature via serper

Referenced by nodes (2)

• Functional MRI concept
• PET concept